BRPI0812461A2 - método de prever a resposta de um indivíduo a uma terapia, método de tratamento de um distúrbio imunológico, composição e kit - Google Patents
método de prever a resposta de um indivíduo a uma terapia, método de tratamento de um distúrbio imunológico, composição e kitInfo
- Publication number
- BRPI0812461A2 BRPI0812461A2 BRPI0812461A BRPI0812461A BRPI0812461A2 BR PI0812461 A2 BRPI0812461 A2 BR PI0812461A2 BR PI0812461 A BRPI0812461 A BR PI0812461A BR PI0812461 A BRPI0812461 A BR PI0812461A BR PI0812461 A2 BRPI0812461 A2 BR PI0812461A2
- Authority
- BR
- Brazil
- Prior art keywords
- predicting
- therapy
- kit
- treating
- individual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- General Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94293707P | 2007-06-08 | 2007-06-08 | |
PCT/US2008/066180 WO2008154423A2 (en) | 2007-06-08 | 2008-06-06 | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0812461A2 true BRPI0812461A2 (pt) | 2017-06-13 |
Family
ID=40130456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0812461A BRPI0812461A2 (pt) | 2007-06-08 | 2008-06-06 | método de prever a resposta de um indivíduo a uma terapia, método de tratamento de um distúrbio imunológico, composição e kit |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100303813A1 (pt) |
EP (2) | EP2617837A3 (pt) |
JP (2) | JP5719591B2 (pt) |
KR (1) | KR20100037590A (pt) |
CN (2) | CN101796197B (pt) |
AU (1) | AU2008261869B2 (pt) |
BR (1) | BRPI0812461A2 (pt) |
CA (1) | CA2690898A1 (pt) |
EA (1) | EA017815B1 (pt) |
IL (2) | IL202562A0 (pt) |
MX (1) | MX2009013410A (pt) |
NO (1) | NO20093488L (pt) |
NZ (1) | NZ581742A (pt) |
SG (1) | SG182183A1 (pt) |
WO (1) | WO2008154423A2 (pt) |
ZA (1) | ZA200909215B (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090235713A1 (en) * | 2008-03-24 | 2009-09-24 | Hirotec America, Inc. | Magnetically actuated roller head |
US8512964B2 (en) | 2008-12-12 | 2013-08-20 | The Regents Of The University Of California | Targets for treatment of hypercholesterolemia |
JP4883117B2 (ja) * | 2009-03-23 | 2012-02-22 | コニカミノルタビジネステクノロジーズ株式会社 | 画像処理装置の課金装置、それを用いた画像処理装置、画像処理装置の課金装置の制御方法、及び画像処理装置の課金装置の制御プログラム |
MX2012002766A (es) | 2009-09-03 | 2012-04-02 | Genentech Inc | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. |
EP3708190A1 (en) | 2010-02-26 | 2020-09-16 | Novo Nordisk A/S | Stable antibody containing compositions |
CA2793137A1 (en) * | 2010-03-24 | 2011-09-29 | Tc Land Expression | Genes and genes combinations predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) |
US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
CA2827859A1 (en) | 2011-02-28 | 2012-09-07 | Genentech, Inc. | Biological markers and methods for predicting response to b-cell antagonists |
WO2013117751A2 (en) | 2012-02-10 | 2013-08-15 | Novo Nordisk A/S | Methods related to treatment of inflammatory diseases and disorders |
US9031292B2 (en) * | 2012-04-19 | 2015-05-12 | Chang Gung University | Method for the diagnosis of neurodegenerative disorder by using diffusion kurtosis imaging |
EP2861767A4 (en) * | 2012-06-15 | 2016-07-27 | Nuclea Biotechnologies Inc | PREDICTIVE MARKERS FOR CANCER AND METAL CHANGE SYNDROME |
US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
ES2524164B1 (es) * | 2013-05-03 | 2015-10-27 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Pronóstico de respuesta al tratamiento con anti-tnfalfa en pacientes de artritis reumatoide |
WO2016040861A1 (en) * | 2014-09-12 | 2016-03-17 | Biogen Ma Inc. | Systems and methods for characterization of multiple sclerosis |
WO2016073768A1 (en) | 2014-11-05 | 2016-05-12 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
US10098168B2 (en) * | 2014-12-08 | 2018-10-09 | Apple Inc. | Neighbor awareness networking datapath |
GB2547406A (en) * | 2015-11-20 | 2017-08-23 | Folkersen Lasse | Apparatus and methods of using of biomarkers for predicting TNF-inhibitor response |
CA3007276C (en) | 2015-12-03 | 2021-12-28 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitor to treat macular degeneration in a patient population |
GB201521357D0 (en) * | 2015-12-03 | 2016-01-20 | Univ Liverpool | Methods for predicting response to anti-TNF therapy |
CN106520771B (zh) * | 2016-12-20 | 2019-02-12 | 江苏省人民医院 | 一种长非编码rna及其在诊断/治疗子痫前期中的应用 |
KR102094802B1 (ko) * | 2017-10-24 | 2020-03-31 | 고려대학교 산학협력단 | 소변 대사체 분석을 이용한 베체트병의 진단방법 |
EP3765634A4 (en) | 2018-03-16 | 2021-12-01 | Scipher Medicine Corporation | METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES |
CN110141578B (zh) * | 2019-06-10 | 2022-06-14 | 南通大学 | 环状RNA circ-Ankib1在制备促进神经再生和修复神经损伤药物中的应用 |
WO2020264426A1 (en) * | 2019-06-27 | 2020-12-30 | Scipher Medicine Corporation | Developing classifiers for stratifying patients |
CA3191195A1 (en) * | 2020-09-01 | 2022-03-10 | Scipher Medicine Corporation | Methods and systems for predicting response to anti-tnf therapies |
CN112180082B (zh) * | 2020-09-27 | 2022-03-08 | 西安交通大学 | Tweak在制备红斑狼疮诊断试剂中的应用 |
RU2749247C1 (ru) * | 2020-09-28 | 2021-06-07 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се | Способ прогнозирования эффективности лечения ревматоидного артрита препаратом олокизумаб на основе генотипирования |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4499052A (en) | 1982-08-30 | 1985-02-12 | Becton, Dickinson And Company | Apparatus for distinguishing multiple subpopulations of cells |
US4582789A (en) | 1984-03-21 | 1986-04-15 | Cetus Corporation | Process for labeling nucleic acids using psoralen derivatives |
US4563417A (en) | 1984-08-31 | 1986-01-07 | Miles Laboratories, Inc. | Nucleic acid hybridization assay employing antibodies to intercalation complexes |
SE458968B (sv) | 1987-06-16 | 1989-05-22 | Wallac Oy | Biospecifikt analysfoerfarande foer flera analyter i vilket ingaar partikelraekning och maerkning med fluorescerande maerksubstanser |
DK641487A (da) | 1987-12-07 | 1989-06-08 | Gluetech Aps | Fremgangsmaade til modificering af polymeroverflader |
US5871928A (en) | 1989-06-07 | 1999-02-16 | Fodor; Stephen P. A. | Methods for nucleic acid analysis |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
EP1231282A3 (en) | 1990-12-06 | 2005-05-18 | Affymetrix, Inc. | Methods and compositions for identification of polymers |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
RU2139092C1 (ru) | 1993-06-03 | 1999-10-10 | Терапьютик Антибодиз Инк. | Фрагменты антител в терапии |
US6027880A (en) | 1995-08-02 | 2000-02-22 | Affymetrix, Inc. | Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis |
US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
FR2707882B1 (fr) | 1993-07-23 | 1997-08-01 | Immunotech Sa | Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant. |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US8017121B2 (en) | 1994-06-30 | 2011-09-13 | Chugai Seiyaku Kabushika Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
US5981180A (en) | 1995-10-11 | 1999-11-09 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and methods |
AU3568897A (en) | 1996-06-07 | 1998-01-05 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
US7060667B1 (en) | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
US6197599B1 (en) | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
US7473528B2 (en) * | 1999-01-06 | 2009-01-06 | Genenews Inc. | Method for the detection of Chagas disease related gene transcripts in blood |
US6410231B1 (en) | 1999-02-26 | 2002-06-25 | Incyte Genomics, Inc. | SNP detection |
US6649414B1 (en) | 1999-08-17 | 2003-11-18 | Luminex Corporation | Microparticles with multiple fluorescent signals and methods of using same |
AU783841B2 (en) | 1999-11-26 | 2005-12-15 | 454 Life Sciences Corporation | Nucleic acid probe arrays |
JP2004500412A (ja) | 2000-03-31 | 2004-01-08 | アイデック ファーマスーティカルズ コーポレイション | B細胞リンパ腫の治療のための抗サイトカイン抗体またはアンタゴニストおよび抗cd20の併用 |
AU2002219164A1 (en) * | 2000-12-08 | 2002-06-18 | Juan Saus | Tnf-inducible promotors and methods for using them |
JP4808365B2 (ja) | 2001-03-02 | 2011-11-02 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Pcr法 |
EP1379545A2 (de) | 2001-04-19 | 2004-01-14 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays |
US6812341B1 (en) | 2001-05-11 | 2004-11-02 | Ambion, Inc. | High efficiency mRNA isolation methods and compositions |
US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
US20030013208A1 (en) | 2001-07-13 | 2003-01-16 | Milagen, Inc. | Information enhanced antibody arrays |
AU2003212822A1 (en) * | 2002-01-22 | 2003-09-02 | Trustees Of The University Of Pennsylvania | Methods for determining drug responsiveness |
AU2003265584C1 (en) | 2002-08-20 | 2009-05-21 | Cyvera Corporation | Diffraction grating-based encoded micro-particles for multiplexed experiments |
US7252976B2 (en) | 2002-08-28 | 2007-08-07 | Board Of Regents The University Of Texas System | Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample |
AU2003261787B2 (en) | 2002-08-30 | 2008-11-06 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human antihuman interleukin-6 antibody and fragment of the antibody |
WO2004025562A1 (en) | 2002-09-12 | 2004-03-25 | Cyvera Corp. | Method and apparatus for labelling using diffraction grating-based encoded optical identification elements |
AU2003270655A1 (en) | 2002-09-12 | 2004-04-30 | Cyvera Corporation | Assay stick comprising coded microbeads |
EP1575707A1 (en) | 2002-09-12 | 2005-09-21 | Cyvera Corporation | Method and apparatus for aligning elongated microbeads in order to interrogate the same |
CA2499046A1 (en) | 2002-09-12 | 2004-03-25 | Cyvera Corporation | Diffraction grating-based encoded micro-particles for multiplexed experiments |
EP1552475A1 (en) | 2002-09-12 | 2005-07-13 | Cyvera Corporation | Chemical synthesis using diffraction grating-based encoded optical elements |
US7092160B2 (en) | 2002-09-12 | 2006-08-15 | Illumina, Inc. | Method of manufacturing of diffraction grating-based optical identification element |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
JP4685369B2 (ja) * | 2004-04-30 | 2011-05-18 | 独立行政法人科学技術振興機構 | 関節リウマチ診断用試薬 |
US20060008823A1 (en) | 2004-05-12 | 2006-01-12 | Kemp Jennifer T | DNA profiling and SNP detection utilizing microarrays |
AR052774A1 (es) * | 2004-10-08 | 2007-04-04 | Wyeth Corp | Inmunoterapia para trastornos autoinmunes |
GB0422417D0 (en) * | 2004-10-08 | 2004-11-10 | Ihg Diagnostics | Improvements in induced heteroduplex generators |
WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
PA8672101A1 (es) | 2005-04-29 | 2006-12-07 | Centocor Inc | Anticuerpos anti-il-6, composiciones, métodos y usos |
ES2432564T3 (es) | 2005-05-10 | 2013-12-04 | Biogen Idec Ma Inc. | Tratamiento y evaluación de trastornos inflamatorios |
CA2612021A1 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
CN100338228C (zh) * | 2005-06-30 | 2007-09-19 | 卫生部北京医院 | 一种预测2型糖尿病易感性的试剂 |
WO2007025085A2 (en) * | 2005-08-24 | 2007-03-01 | Genizon Biosciences Inc. | Genemap of the human genes associated with crohn's disease |
WO2007038501A2 (en) * | 2005-09-27 | 2007-04-05 | The Feinstein Institute For Medical Research | Rheumatoid arthritis markers |
EP1857559A1 (en) * | 2006-05-16 | 2007-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for predicting responsiveness to TNF alpha blocking agents |
US20080293582A1 (en) * | 2006-08-30 | 2008-11-27 | Xilin Li | Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel |
WO2008132176A2 (en) * | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Method for evaluating the response of an individual to tnf blocking therapy |
-
2008
- 2008-06-06 EA EA200971131A patent/EA017815B1/ru not_active IP Right Cessation
- 2008-06-06 US US12/663,335 patent/US20100303813A1/en not_active Abandoned
- 2008-06-06 AU AU2008261869A patent/AU2008261869B2/en not_active Ceased
- 2008-06-06 CN CN200880102360.5A patent/CN101796197B/zh not_active Expired - Fee Related
- 2008-06-06 EP EP20130160408 patent/EP2617837A3/en not_active Withdrawn
- 2008-06-06 SG SG2012042255A patent/SG182183A1/en unknown
- 2008-06-06 JP JP2010511381A patent/JP5719591B2/ja active Active
- 2008-06-06 NZ NZ581742A patent/NZ581742A/xx not_active IP Right Cessation
- 2008-06-06 WO PCT/US2008/066180 patent/WO2008154423A2/en active Application Filing
- 2008-06-06 CA CA2690898A patent/CA2690898A1/en not_active Abandoned
- 2008-06-06 CN CN201410012312.4A patent/CN103710458A/zh active Pending
- 2008-06-06 MX MX2009013410A patent/MX2009013410A/es not_active Application Discontinuation
- 2008-06-06 EP EP08770385A patent/EP2167687B1/en active Active
- 2008-06-06 KR KR1020107000339A patent/KR20100037590A/ko not_active Application Discontinuation
- 2008-06-06 BR BRPI0812461A patent/BRPI0812461A2/pt not_active Application Discontinuation
-
2009
- 2009-12-07 IL IL202562A patent/IL202562A0/en unknown
- 2009-12-08 NO NO20093488A patent/NO20093488L/no not_active Application Discontinuation
- 2009-12-23 ZA ZA200909215A patent/ZA200909215B/xx unknown
-
2012
- 2012-12-04 IL IL223419A patent/IL223419A0/en unknown
-
2013
- 2013-10-31 JP JP2013226708A patent/JP2014033676A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP2167687A2 (en) | 2010-03-31 |
AU2008261869A1 (en) | 2008-12-18 |
CN101796197B (zh) | 2014-02-12 |
JP2014033676A (ja) | 2014-02-24 |
EP2167687A4 (en) | 2010-10-13 |
EP2617837A2 (en) | 2013-07-24 |
CN101796197A (zh) | 2010-08-04 |
ZA200909215B (en) | 2010-09-29 |
IL223419A0 (en) | 2013-02-03 |
EA017815B1 (ru) | 2013-03-29 |
CN103710458A (zh) | 2014-04-09 |
IL202562A0 (en) | 2011-08-01 |
SG182183A1 (en) | 2012-07-30 |
EP2167687B1 (en) | 2013-03-27 |
WO2008154423A2 (en) | 2008-12-18 |
CA2690898A1 (en) | 2008-12-18 |
US20100303813A1 (en) | 2010-12-02 |
MX2009013410A (es) | 2010-03-22 |
NO20093488L (no) | 2010-01-08 |
JP2010529464A (ja) | 2010-08-26 |
AU2008261869B2 (en) | 2014-12-18 |
EA200971131A1 (ru) | 2010-06-30 |
KR20100037590A (ko) | 2010-04-09 |
JP5719591B2 (ja) | 2015-05-20 |
EP2617837A3 (en) | 2013-10-23 |
WO2008154423A3 (en) | 2009-02-05 |
NZ581742A (en) | 2012-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0812461A2 (pt) | método de prever a resposta de um indivíduo a uma terapia, método de tratamento de um distúrbio imunológico, composição e kit | |
BRPI0820568A2 (pt) | Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal | |
BRPI0815459A2 (pt) | "composição, método de tratamento de um substrato e método de tratamento de uma superfície doméstica" | |
BR112013009142A2 (pt) | "composição modeladora de fibra queratinosa, kit modelador de fibra queratinosa e métod para tratamento de uma fibra queratinosa" | |
BRPI0817271A2 (pt) | Método de tratamento da doença de parkinson e outros distúrbios relacionados | |
DK2358756T4 (da) | Humane antistoffer med høj affinitet til PCSK9 | |
BRPI0821658A2 (pt) | Anticorpos contra nkg2d humano e usos dos mesmos | |
EP2120580A4 (en) | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | |
BRPI0915986A2 (pt) | composição, métodos para tratar uma condição, para retardar o início de uma condição, para reduzir o risco em um indivíduo de adquirir uma condição e para alterar a expressão de um ou mais genes em um indivíduo | |
DK2068874T3 (da) | Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer | |
HK1146894A1 (en) | Compositions and methods for treating diseases of the nail | |
BRPI0909180A2 (pt) | composição farmacêutica, e, método de tratamento de uma doença autoimune | |
BRPI0909048A2 (pt) | composição farmacêutica, e, método de tratamento de uma doença autoimune | |
GB0912941D0 (en) | Methods and composition for reduction of side effects of therapeutic treatments | |
FR2939033B1 (fr) | Composition cosmetique de maquillage et/ou de soin des matieres keratiniques, et procede de maquillage | |
ZA200807802B (en) | Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis | |
EP1768678A4 (en) | METHODS FOR SELECTIVE TREATMENT OF DISEASES BY SPECIFIC GLYCOSAMINOGLYCAN POLYMERS | |
HK1131553A1 (zh) | 用於治療皮膚的美容組合物以及用於治療皮膚的方法 | |
EP2234625B8 (en) | Compositions and methods for treating and preventing skeletal muscle deficiencies | |
EP2051732A4 (en) | DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR | |
DK2040565T3 (da) | Sammensætninger og fremgangsmåder til forebyggelse eller behandling af kardiovaskulære sygdomme i katte med hyperthyroidisme | |
BR112012027531A2 (pt) | método de tratamento e/ou prevenção de progresso e/ou atraso de desenvolvimento de hepatite em um indivíduo, uso de uma molécula imunológica anti-cd3 e composição farmacêutica | |
EP1926824A4 (en) | METHOD FOR DETERMINING REACTIVITY TO ERYTROPOIETIN TREATMENT | |
FR2926020B1 (fr) | Composition cosmetique et/ou dermatologique | |
EP2096927A4 (en) | THERAPEUTIC COMPOSITIONS AND METHODS OF TREATING WITH CAPSIANOSIDE COMPOUNDS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |